Hyponatraemia in heart failure.
acute heart failure
chronic heart failure
hyponatraemia
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
27
02
2019
revised:
16
08
2019
accepted:
18
08
2019
pubmed:
27
8
2019
medline:
28
4
2021
entrez:
27
8
2019
Statut:
ppublish
Résumé
Hyponatraemia is common in heart failure (HF). It is estimated that over 20% of patients admitted to hospital with HF have hyponatraemia. It has also been repeatedly shown to be a surrogate marker of increased morbidity and mortality in this specific population. This review focuses on the pathophysiology of hyponatraemia through the activation of neurohormonal cascades in HF, the clinical implications of sustained hyponatraemia and treatment options in the management of this challenging phenomenon.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-666Informations de copyright
© 2019 Royal Australasian College of Physicians.
Références
Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980-8.
Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010; 170: 294-302.
Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (Lond) 1982; 62: 465-9.
Verbrugge F, Steels P, Grieten L, Nijst P, Tang W, Mullens W. Hyponatremia in acute decompensated heart failure - depletion versus dilution. JACC 2015; 65: 480-92.
Swedberg K, Idanpaan-Heikkila U, Remes J. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
Yusuf S, Nicklas JM, Timmis G et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. Expert Opin Drug Saf 2010; 9: 259-73.
Kazory A. Hyponatremia in heart failure: revisiting pathophysiology and therapeutic strategies. Clin Cardiol 2010; 33: 322-9.
Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One 2013; 8: e80451.
Sato N, Gheorghiade M, Kajimoto K, Munakata R, Minami Y, Mizuno M et al. Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry). Am J Cardiol 2013; 111: 1019-25.
Georghiade M, Rossi JS, Cotts W et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007; 167: 1998-2005.
Lilly LS, Dzau VJ, Williams GH. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metabol 1984; 59: 924-30.
Boron WF, Boulpaep EL, eds. Medical Physiology: A Cellular and Molecular Approach. Philadelphia, PA: Saunders Elsevier; 2009.
Suckling RJ, He FJ, Markandu ND, MacGregor GA. Dietary salt influences postprandial plasma sodium concentration and systolic blood pressure. Kidney Int 2012; 81: 407-11.
Spasvoski G, Vanholder R, ALlolio B, Annane D, Ball S, Bichet D et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014; 170: G1-G47.
Sequeira Lopez ML, Pentz ES, Nomasa T, Smithies O, Gomez RA. Renin cells are precursors for multiple cell types that switch to the renin phenotype when homeostasis is threatened. Dev Cell 2004; 6: 719-28.
Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. Dysregulation of the renin-angiotensin system and the vasopressinergic system interactions in cardiovascular disorders. Curr Hypertens Rep 2018; 20: 19.
Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Cardiorenal syndrome: role of arginine vasopressin and Vaptans in heart failure. Cardiol Res 2017; 8: 87-95.
Fitzsimons J. Angiotensin, thirst, and sodium appetite. Physiol Res 1998; 78: 583-686.
Park F, Mattson DL, Skelton MM, Cowley AW. Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation. Am J Physiol Regul Integr Comp Physiol 1997; 273: R243-51.
Hayashi M, Sasaki S, Tsuganezawa H, Monkawa T, Kitajima W, Konishi K et al. Role of vasopressin V2 receptor in acute regulation of aquaporin-2. Kidney Blood Press Res 1996; 19: 32-7.
Imamura T, Kinugawa K, Hatano M, Fujino T, Inaba T, Maki H et al. Low cardiac output stimulates vasopressin release in patients with stage d heart failure. Circ J 2014; 78: 2259-67.
Romanovsky A, Bagshaw S, Rosner MH. Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy. Int J Nephrol 2011; 2011: 732746.
Aylwin S, Burst V, Peri A, Runkle I, Thatcher N. 'Dos and don'ts' in the management of hyponatremia. Curr Med Res Opin 2015; 31: 1755-61.
Sterns RH, Hix JK, Silver S. Treating profound hyponatremia: a strategy for controlled correction. Am J Kidney Dis 2010; 56: 774-9.
Lai MY, Lin CC, Chung SL, Wu CH, Yang WC, Tseng YT. Milky plasma, diabetes, and severe hyponatremia. Kidney Int 2009; 75: 996.
Ali SS, Olinger CC, Sobotka PA, Dahle TGA, Bunte MC, Blake D et al. Randomized aldactone evaluation study investigators. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail 2009; 15: 1-4.
Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WHW et al. The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'. Eur J Heart Fail 2014; 16: 133-42.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297: 1319-31.
Hauptman PJ, Burnett K, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D et al. Clinical course of patients with hyponatraemia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan. J Card Fail 2013; 19: 390-7.
Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-9.
Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417-23.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407.
Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-6.
Palmer BF, Rock AD, Woodward EJ. Dose comparison of conivaptan (Vaprisol(R)) in patients with euvolemic or hypervolemic hyponatremia - efficacy, safety, and pharmacokinetics. Drug Des Devel Ther 2016; 10: 339-51.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.
Nakada Y, Okayama S, Nakano T, Ueda T, Onoue K, Takeda Y et al. Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study. Cardiovasc Ultrasound 2015; 13: 27.
Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol 2015; 70: 217-23.
Shanmugam E, Doss CR, George M, Jena A, Rajaram M, Ramaraj B et al. Effect of tolvaptan on acute heart failure with hyponatremia - a randomized, double blind, controlled clinical trial. Indian Heart J 2016; 68: S15-21.